Drugs / rolofyline
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00652782 | Dec 2004 → Aug 2005 | congestive heart failure, impaired renal function disease | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rolofyline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00652782 ↗ |
| Route | Intravenous | “rolofyline 2.5 mg IV QD” NCT00652782 ↗ |